Lataa...

Application of CRISPR/Cas9 Technology to HBV

More than 240 million people around the world are chronically infected with hepatitis B virus (HBV). Nucleos(t)ide analogs and interferon are the only two families of drugs to treat HBV currently. However, none of these anti-virals directly target the stable nuclear covalently closed circular DNA (c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Guigao Lin, Kuo Zhang, Jinming Li
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MDPI AG 2015-11-01
Sarja:International Journal of Molecular Sciences
Aiheet:
HBV
Linkit:http://www.mdpi.com/1422-0067/16/11/25950
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!